2020年左右阳性非小细胞肺癌中5'融合伙伴目录
A Catalog of 5' Fusion Partners in -Positive NSCLC Circa 2020.
作者信息
Ou Sai-Hong Ignatius, Nagasaka Misako
机构信息
Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California.
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
出版信息
JTO Clin Res Rep. 2020 Apr 28;1(3):100048. doi: 10.1016/j.jtocrr.2020.100048. eCollection 2020 Sep.
Abstract
fusion-positive () NSCLC was discovered in 2007, the same year as the discovery of -positive (+) NSCLC but has trailed + NSCLC in terms of development. There seems to be a differential response to ROS1 inhibitors, which depend on fusion partners (CD74, SLC34A2, or SDC4); thus, knowledge of the fusion partners in NSCLC is important. To date (end of February 2020), we have identified 24 unique 5' fusion partners of in NSCLC from published literature and congress proceedings. Thus, we published this catalog for easy reference.
摘要
融合阳性（）非小细胞肺癌于2007年被发现，同年发现了阳性（+）非小细胞肺癌，但在发展方面落后于+非小细胞肺癌。对于ROS1抑制剂似乎存在不同的反应，这取决于融合伴侣（CD74、SLC34A2或SDC4）；因此，了解非小细胞肺癌中的融合伴侣很重要。截至（2020年2月底），我们已从已发表的文献和会议记录中确定了非小细胞肺癌中24个独特的5'融合伴侣。因此，我们发布此目录以便于参考。
相似文献
1
A Catalog of 5' Fusion Partners in -Positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Apr 28;1(3):100048. doi: 10.1016/j.jtocrr.2020.100048. eCollection 2020 Sep.
2
Catalog of 5' fusion partners in NSCLC Circa 2020.2020年前后非小细胞肺癌中5'融合伴侣目录
JTO Clin Res Rep. 2020 Mar 30;1(2):100037. doi: 10.1016/j.jtocrr.2020.100037. eCollection 2020 Jun.
3
Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.基于下一代测序技术鉴定的 ROS1 重排非小细胞肺癌的分子和临床病理特征。
Mol Oncol. 2020 Nov;14(11):2787-2795. doi: 10.1002/1878-0261.12789. Epub 2020 Sep 14.
4
Catalog of 5' Fusion Partners in -positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Feb 19;1(1):100015. doi: 10.1016/j.jtocrr.2020.100015. eCollection 2020 Mar.
5
Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.非常见 ALK、ROS1 和 RET 基因组断裂点预测 NSCLC 靶向治疗疗效的潜在不可靠性。
J Thorac Oncol. 2021 Mar;16(3):404-418. doi: 10.1016/j.jtho.2020.10.156. Epub 2020 Nov 26.
6
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.ROS1 阳性非小细胞肺癌患者在常规临床实践中的特征和结局。
J Thorac Oncol. 2018 Sep;13(9):1373-1382. doi: 10.1016/j.jtho.2018.05.026. Epub 2018 Jun 5.
7
A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.一种与CD74-ROS1融合共存的新型ROS1-FBXL17融合可能提高对克唑替尼的敏感性并延长肺腺癌患者的无进展生存期。
Onco Targets Ther. 2020 Nov 10;13:11499-11504. doi: 10.2147/OTT.S278907. eCollection 2020.
8
CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.ROS1 阳性非小细胞肺癌中的中枢神经系统转移：了解并克服这一紧急问题的迫切需求。
Lung Cancer. 2019 Apr;130:201-207. doi: 10.1016/j.lungcan.2019.02.025. Epub 2019 Feb 22.
9
Different Types of Fusion Partners Yield Comparable Efficacy to Crizotinib.不同类型的融合伙伴与克唑替尼疗效相当。
Oncol Res. 2019 Aug 8;27(8):901-910. doi: 10.3727/096504019X15509372008132. Epub 2019 Mar 25.
10
Detection of gene fusions using next-generation sequencing for patients with malignancy in China.在中国，使用下一代测序技术对恶性肿瘤患者进行基因融合检测。
Front Cell Dev Biol. 2022 Dec 15;10:1035033. doi: 10.3389/fcell.2022.1035033. eCollection 2022.
引用本文的文献
1
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.齐德替尼对多种ROS1耐药突变的选择性靶向作用。
Mol Cancer Ther. 2025 Jul 2;24(7):1005-1019. doi: 10.1158/1535-7163.MCT-25-0025.
2
Resistance mechanisms of non-small cell lung cancer and improvement of treatment effects through nanotechnology: a narrative review.非小细胞肺癌的耐药机制及通过纳米技术改善治疗效果：一篇叙述性综述
J Thorac Dis. 2024 Nov 30;16(11):8039-8052. doi: 10.21037/jtd-24-1078. Epub 2024 Nov 15.
3
Discovery of Oral Degraders of the ROS1 Fusion Protein with Potent Activity against Secondary Resistance Mutations.发现具有针对次级耐药突变强效活性的 ROS1 融合蛋白口服降解剂。
J Med Chem. 2024 Oct 24;67(20):18098-18123. doi: 10.1021/acs.jmedchem.4c01205. Epub 2024 Oct 3.
4
Advances and future directions in ROS1 fusion-positive lung cancer.ROS1 融合阳性肺癌的研究进展及未来方向
Oncologist. 2024 Nov 4;29(11):943-956. doi: 10.1093/oncolo/oyae205.
5
: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.通过下一代测序检测到一种新型ROS1致癌融合基因。
Clin Pathol. 2024 Aug 12;17:2632010X241269373. doi: 10.1177/2632010X241269373. eCollection 2024 Jan-Dec.
6
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.致癌酪氨酸激酶融合在人类癌症中的机制模式和临床意义。
Nat Commun. 2024 Jun 14;15(1):5110. doi: 10.1038/s41467-024-49499-0.
7
Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.目前针对恶性肿瘤 ROS1 靶向治疗的治疗方法和新见解。
Cancer Med. 2024 Apr;13(8):e7201. doi: 10.1002/cam4.7201.
8
KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.KLC1-ROS1融合通过JAK-STAT通路的特异性激活发挥胶质瘤细胞的致癌特性。
Cancers (Basel). 2023 Dec 19;16(1):9. doi: 10.3390/cancers16010009.
9
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.间变性淋巴瘤激酶抑制剂——抗癌特性、临床疗效及耐药机制综述
Front Pharmacol. 2023 Oct 25;14:1285374. doi: 10.3389/fphar.2023.1285374. eCollection 2023.
10
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.通过下一代 RNA 和全转录组测序检测到的 ROS1 融合的泛肿瘤分析。
BMC Cancer. 2023 Oct 18;23(1):1000. doi: 10.1186/s12885-023-11457-2.
本文引用的文献
1
Catalog of 5' fusion partners in NSCLC Circa 2020.2020年前后非小细胞肺癌中5'融合伴侣目录
JTO Clin Res Rep. 2020 Mar 30;1(2):100037. doi: 10.1016/j.jtocrr.2020.100037. eCollection 2020 Jun.
2
Catalog of 5' Fusion Partners in -positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Feb 19;1(1):100015. doi: 10.1016/j.jtocrr.2020.100015. eCollection 2020 Mar.
3
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.一项多中心研究，旨在探讨 ROS1 重排非小细胞肺癌患者的血栓栓塞事件。
Lung Cancer. 2020 Apr;142:34-40. doi: 10.1016/j.lungcan.2020.01.017. Epub 2020 Jan 22.
4
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.恩曲替尼治疗 ROS1 融合阳性非小细胞肺癌：三项 1 期-2 期临床试验的汇总分析。
Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
5
Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.一名对克唑替尼敏感的微卫星不稳定晚期肺腺癌青少年患者中新型RBPMS-ROS1融合的鉴定：病例报告
Clin Lung Cancer. 2020 Mar;21(2):e78-e83. doi: 10.1016/j.cllc.2019.09.003. Epub 2019 Sep 26.
6
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).ROS1 重排非小细胞肺癌与高静脉血栓栓塞率相关：来自 II 期、前瞻性、多中心、双臂试验（METROS）的分析。
Clin Lung Cancer. 2020 Jan;21(1):15-20. doi: 10.1016/j.cllc.2019.06.012. Epub 2019 Jun 18.
7
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.ROS1-ADGRG6：肺腺癌中一种新型 ROS1 致癌融合变异的病例报告及对克唑替尼的反应。
BMC Cancer. 2019 Aug 5;19(1):769. doi: 10.1186/s12885-019-5948-y.
8
Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.获得性受体酪氨酸激酶融合作为对表皮生长因子受体酪氨酸激酶抑制剂耐药机制的特征分析
Cancer Manag Res. 2019 Jul 9;11:6343-6351. doi: 10.2147/CMAR.S197337. eCollection 2019.
9
Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.鉴定肺腺癌中对克唑替尼敏感的新型 WNK1-ROS1 融合。
Lung Cancer. 2019 Mar;129:92-94. doi: 10.1016/j.lungcan.2018.12.011. Epub 2018 Dec 19.
10
: a novel gene fusion in hepatic angiosarcoma.肝血管肉瘤中的一种新型基因融合
Oncotarget. 2019 Jan 4;10(2):245-251. doi: 10.18632/oncotarget.26521.
Zotero 插件